ABVC BioPharma, Inc. (ABVC)
NASDAQ:ABVC
Top Page
ABVC BioPharma
(NASDAQ:ABVC)
Select Model
Select Model
Rating:45Neutral
Price Target:
$1.50
▼(-28.57% Downside)
Action:ReiteratedDate:04/07/26
The score is primarily held down by weak financial performance—tiny and volatile revenue, large ongoing losses, and historically negative cash flow—despite improved 2025 leverage. Technicals are mixed (short-term firmness but still below key longer-term averages), valuation is constrained by negative earnings, and the latest corporate event is modestly supportive but not transformative.
Positive Factors
Improved leverage
The material improvement in leverage (debt-to-equity ~0.31 in 2025) meaningfully lowers near-term default and refinancing risk for a cash-burning clinical-stage biopharma. A stronger balance sheet provides more runway to advance trials or pursue out-licensing before urgent dilutive funding is required.
Negative Factors
Weak cash generation
The company lacks consistent internal cash generation, with 2025 operating/free cash flow at $0 and prior years deeply negative. Persistent cash deficits force reliance on external capital, raising dilution and financing risk and constraining the firm's ability to fund clinical milestones independently over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved leverage
The material improvement in leverage (debt-to-equity ~0.31 in 2025) meaningfully lowers near-term default and refinancing risk for a cash-burning clinical-stage biopharma. A stronger balance sheet provides more runway to advance trials or pursue out-licensing before urgent dilutive funding is required.
Read all positive factors
ABVC BioPharma (ABVC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$36.38M
Dividend YieldN/A
Average Volume (3M)95.05K
Price to Earnings (P/E)―
Beta (1Y)1.84
Revenue Growth56.52%
EPS Growth75.22%
CountryUS
Employees16
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.11
Shares Outstanding25,440,407
10 Day Avg. Volume116,541
30 Day Avg. Volume95,045
Financial Highlights & Ratios
PEG Ratio0.88
Price to Book (P/B)4.46
Price to Sales (P/S)62.24
P/FCF Ratio-16.56
Enterprise Value/Market Cap0.65
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit40.41
Enterprise Value/Ebitda-3.94
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.3
Revenue Forecast (FY)$35.28M
ABVC BioPharma Business Overview & Revenue Model
Company Description
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination ther...
How the Company Makes Money
ABVC’s business model is centered on monetizing its drug-development pipeline rather than selling established, marketed pharmaceutical products. The company can generate revenue primarily through (1) out-licensing and partnering transactions for i...
ABVC BioPharma Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
46
Neutral
Cash Flow
12
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 795.95K | 509.59K | 152.43K | 969.78K | 355.80K |
| Gross Profit | 795.95K | 508.83K | -149.61K | 683.37K | 350.71K |
| EBITDA | -6.65M | -4.34M | -6.33M | -15.20M | -10.97M |
| Net Income | -7.91M | -4.90M | -7.79M | -16.42M | -12.84M |
Balance Sheet | |||||
| Total Assets | 21.06M | 7.54M | 7.78M | 10.93M | 13.70M |
| Cash, Cash Equivalents and Short-Term Investments | 745.83K | 928.55K | 796.09K | 1.47M | 5.94M |
| Total Debt | 3.47M | 3.20M | 2.77M | 3.41M | 3.34M |
| Total Liabilities | 7.76M | 6.82M | 6.53M | 6.34M | 4.83M |
| Stockholders Equity | 11.11M | 1.23M | 1.55M | 4.45M | 8.84M |
Cash Flow | |||||
| Free Cash Flow | -2.99M | -1.81M | -4.21M | -7.52M | -7.62M |
| Operating Cash Flow | -2.99M | -1.81M | -4.19M | -7.40M | -7.60M |
| Investing Cash Flow | -1.21M | 0.00 | -360.19K | -1.72M | -805.97K |
| Financing Cash Flow | 4.64M | 1.98M | 3.87M | 4.01M | 10.00M |
ABVC BioPharma Technical Analysis
Neutral
2.10
Price Trends
1.46
Negative
1.90
Negative
2.44
Negative
Market Momentum
-0.05
Negative
56.85
Neutral
70.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABVC, the sentiment is Neutral. The current price of 2.1 is above the 20-day moving average (MA) of 1.21, above the 50-day MA of 1.46, and below the 200-day MA of 2.44, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 56.85 is Neutral, neither overbought nor oversold. The STOCH value of 70.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ABVC.
ABVC BioPharma Risk Analysis
ABVC BioPharma disclosed 48 risk factors in its most recent earnings report. ABVC BioPharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
Cybersecurity incidents and decentralization of documents may hurt the company's business, damage its reputation, increase its costs, and cause losses. Q4, 2023
ABVC BioPharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $56.96M | >-0.01 | ― | ― | ― | 21.48% | |
48 Neutral | $37.31M | -2.65 | -96.04% | ― | -38.81% | -76.96% | |
47 Neutral | $233.12M | -2.32 | -162.49% | ― | ― | 5.51% | |
46 Neutral | $52.32M | ― | -63.13% | ― | -17.94% | 21.43% | |
45 Neutral | $36.38M | -3.48 | -88.89% | ― | 56.52% | 75.22% | |
43 Neutral | $23.06M | -0.46 | -191.12% | ― | ― | -24.38% |
* Healthcare Sector Average
ABVC
ABVC BioPharma
1.43
0.38
36.19%
CRVO
CervoMed
4.03
-4.44
-52.42%
HYFT
MindWalk Holdings
1.12
0.72
179.30%
JSPR
Jasper Therapeutics
0.82
-2.89
-77.82%
INKT
MiNK Therapeutics
11.47
3.89
51.32%
CAMP
CAMP4 Therapeutics Corporation
4.49
2.39
113.81%
ABVC BioPharma Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
ABVC BioPharma Shareholders Back Board, Equity Plan Changes
Positive
Mar 27, 2026
On March 26, 2026, ABVC BioPharma held its 2026 annual shareholder meeting, where investors re-elected 11 directors to the board, each to serve until the 2027 annual meeting. The vote showed strong support for the existing leadership slate, with a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.